P9-7 Treatment outcome following nivolumab therapy administered after radiation therapy for esophageal cancer

Abstract

Nivolumab is an immune checkpoint inhibitor that has been approved since February 2020 for the treatment of unresectable advanced/recurrent esophageal cancer that has worsened after initial chemotherapy. Although the treatment response rate is low at approximately 20%, it has been reported that the administration of nivolumab after irradiation enhances the antitumor effect in cases of esophageal and head and neck cancers. Therefore, we examined cases of nivolumab administration after irradiation of esophageal tumors in our department.